1) Margin on IQBuds is improving with scale and new Nuheara BOOST margin is even higher than IQbuds. And thats right, demand for both products has already been proven. 6 month sales growth for IQBuds was approx. 50%.
2) not sure the relevance.
3) both NUH products are also first of their kind (in the world).
4) Many more people suffer from hearing loss than autism. "About 20 percent of Americans, 48 million, report some degree of hearing loss. At age 65, one out of threepeople has a hearing loss. 60 percent of the people with hearing loss are either in the work force or in educational settings" http://www.hearingloss.org/content/basic-facts-about-hearing-loss
Nuheara is also looking at various other products to compliment existing products offered and tap new markets. Basically everyone that uses there ears to hear things
5) protected IP specific to NUH.
NUH is futher advanced and entering a bigger market. Should be valued more than 2:3.
Nuheara is still very much in business development. Still adding products. Still expanding distribution. It is still in its infancy, and growing very rapidly.
So as soon as NTI gets FDA approval the share price will crash because it aint making any cash? I should be good bloke and let all your mates over there know the risk they are exposed to!
P.s. check this link regarding FDA and NUH. Yep, already ticked that box. And do you notice anything interesting about the comment dated 13th April?
http://www.hearingreview.com/2017/08/president-trump-signs-otc-hearing-aid-legislation-law/
There is an awful lot to suggest this will grow. And grow fast.
Add to My Watchlist
What is My Watchlist?
